On October 13, 2025, Morgan Stanley released a report stating that it expects Alibaba Health's cloud business revenue to accelerate to a 32% year-on-year growth rate in the second quarter of fiscal year 2026 (ending at the end of September this year), with the cloud business EBITA margin remaining at 8%-9%. This will strengthen its position as 'China's Best AI Enabler,' offsetting short-term profitability pressures. Morgan Stanley reiterates its 'Overweight' rating on its ADR.